3M CO MMM
Last close
168.56
2026-09-04
Market cap
$86.93B
2026-06-30 share count
52-week range
139.34 - 184.90
Valuation FY2025 figures against the last close
P/S3.5x
P/E28.1x
P/FCF62.3x
EV/EBITDA15.9x
Dividend yield1.8%
Diluted EPS6.00
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.95B | $24.57B | $24.61B | $26.16B | $35.35B | $32.18B | $32.14B | $32.77B | $31.66B | $30.11B |
| Cost of revenue | $14.99B | $14.45B | $14.98B | $15.85B | $18.80B | $16.61B | $17.14B | $16.68B | $16.05B | $15.12B |
| Gross profit | $9.96B | $10.13B | $9.63B | $10.31B | $16.56B | $15.58B | $15.00B | $16.08B | $15.60B | $14.99B |
| R&D | — | $700.0M | $700.0M | $800.0M | $1.20B | $1.10B | $1.25B | $1.25B | $1.35B | $1.25B |
| SG&A | $4.00B | $4.22B | $19.20B | $7.23B | $7.20B | $6.93B | $7.03B | $7.60B | $6.63B | $6.31B |
| Total operating expenses | $20.32B | $19.75B | $35.30B | $21.79B | $27.99B | $25.02B | $25.96B | $25.56B | $23.96B | $23.08B |
| Operating income | $4.63B | $4.82B | -$10.69B | $4.37B | $7.37B | $7.16B | $6.17B | $7.21B | $7.69B | $7.03B |
| Interest expense | $946.0M | $1.19B | $941.0M | $462.0M | $488.0M | $529.0M | $448.0M | $350.0M | $322.0M | $199.0M |
| Pre-tax income | $4.21B | $4.82B | -$11.27B | $4.20B | $7.20B | $6.79B | $5.64B | $7.00B | $7.55B | $7.05B |
| Income tax | $1.00B | $804.0M | $2.87B | $188.0M | $1.28B | $1.34B | $1.11B | $1.64B | $2.68B | $2.00B |
| Net income | $3.25B | $4.17B | -$7.00B | $5.78B | $5.92B | $5.45B | $4.52B | $5.35B | $4.86B | $5.05B |
| EPS, basic | 6.05 | 7.58 | -12.63 | 10.21 | 10.23 | 9.43 | 7.83 | 9.09 | 8.13 | 8.35 |
| EPS, diluted | 6.00 | 7.55 | -12.63 | 10.18 | 10.12 | 9.36 | 7.72 | 8.89 | 7.93 | 8.16 |
| Shares, diluted (wtd. avg.) | $541.3M | $552.4M | $553.9M | $567.6M | $585.3M | $582.2M | $585.1M | $602.0M | $612.7M | $618.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.24B | $5.60B | $5.93B | $3.65B | $4.56B | $4.63B | — | $2.85B | $3.05B | $2.40B |
| Short-term investments | — | — | — | — | — | $404.0M | $98.0M | $380.0M | $1.08B | — |
| Receivables | $3.53B | $3.19B | $3.60B | $4.53B | $4.66B | $4.71B | $4.79B | $5.02B | $4.91B | $4.39B |
| Inventory | $3.66B | $3.70B | $3.94B | $5.37B | $4.99B | $4.24B | $4.13B | $4.37B | $4.03B | $3.38B |
| Total current assets | $16.39B | $15.88B | $16.38B | $14.69B | $15.40B | $14.98B | $12.97B | $13.71B | $14.28B | $11.73B |
| Property, plant and equipment | $7.10B | $7.39B | $7.69B | $9.18B | $9.43B | $9.42B | $9.33B | $8.74B | $8.87B | $8.52B |
| Goodwill | $6.42B | $6.28B | $6.38B | $6.34B | $13.49B | $13.80B | $13.44B | $10.05B | $10.51B | $9.17B |
| Other intangibles | $1.10B | $1.21B | $1.32B | $4.70B | $5.29B | $5.83B | $6.38B | $2.66B | $2.94B | $2.32B |
| Total assets | $37.73B | $39.87B | $50.58B | $46.45B | $47.07B | $47.34B | $44.66B | $36.50B | $37.99B | $32.91B |
| Accounts payable | $2.70B | $2.66B | $2.78B | $3.18B | $2.99B | $2.56B | $2.23B | $2.27B | $1.95B | $1.80B |
| Short-term debt | $1.67B | $1.92B | $1.15B | $1.94B | $1.29B | $794.0M | $2.79B | $1.21B | $1.85B | $972.0M |
| Total current liabilities | $9.60B | $11.26B | $15.30B | $9.52B | $9.04B | $7.95B | $9.22B | $7.24B | $7.69B | $6.22B |
| Long-term debt | $10.93B | $11.12B | $13.09B | $14.00B | $16.06B | $17.99B | $17.52B | $13.41B | $12.10B | $10.68B |
| Total liabilities | $32.99B | $35.97B | $45.71B | $31.68B | $31.95B | $34.41B | $34.53B | $26.65B | $26.36B | $22.56B |
| Retained earnings | $38.26B | $36.80B | $37.48B | $47.95B | $45.82B | $43.82B | $42.13B | $40.64B | $39.12B | $37.91B |
| Total equity | $4.70B | $3.84B | $4.87B | $14.77B | $15.12B | $12.93B | $10.13B | $9.85B | $11.62B | $10.34B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.31B | $1.82B | $6.68B | $5.59B | $7.45B | $8.11B | $7.07B | $6.44B | $6.24B | $6.66B |
| Depreciation and amortisation | $1.31B | $1.36B | $1.99B | $1.83B | $1.92B | $1.91B | $1.59B | $1.49B | $1.54B | $1.47B |
| Stock-based compensation | $225.0M | $289.0M | $274.0M | $263.0M | $274.0M | $262.0M | $278.0M | $302.0M | $324.0M | $298.0M |
| Capital expenditure | $910.0M | $1.18B | $1.61B | $1.75B | $1.60B | $1.50B | $1.70B | $1.58B | $1.37B | $1.42B |
| Investing cash flow | $1.35B | -$3.21B | -$1.21B | -$1.05B | -$1.32B | -$580.0M | -$6.44B | $222.0M | -$3.09B | -$1.40B |
| Financing cash flow | -$4.02B | $1.10B | -$3.15B | -$5.35B | -$6.14B | -$5.30B | -$1.12B | -$6.70B | -$2.65B | -$4.63B |
| Dividends paid | $1.56B | $1.98B | $3.31B | $3.37B | $3.42B | $3.39B | $3.32B | $3.19B | $2.80B | $2.68B |
| Buybacks | $3.25B | $1.80B | $33.0M | $1.46B | $2.20B | $368.0M | $1.41B | $4.87B | $2.07B | $3.75B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000066740-26-000014.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |
| SOLV | Solventum Corp | $15.61B | 10.3x | 0.9% |